American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology’s (ASCO) new living guideline update, Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, is now available. Updated recommendations include that clinicians can now consider osimertinib combined with platinum-based chemotherapy or the combination of amivantamab and lazertinib as potential treatment options. Read more: https://brnw.ch/21wR0ff

Review our latest living guideline update, Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations, is now available. The latest recommendations expand treatment options to include trastuzumab deruxtecan for patients with HER2-overexpressing NSCLC, defined as HER2 IHC 3+ (gastric scoring). Read more: https://brnw.ch/21wR0fa

Exciting news! The JCO Journals page is now live! Your dedicated hub for the latest breakthroughs, expert insights, and practical guidance from all six ASCO journals. Stay ahead in cancer research and care—follow us now for real-time updates and invaluable resources!

We are committed to advancing policies that improve patient access to high-quality cancer care. We continue to collaborate with all stakeholders to address existing barriers and ultimately improve cancer care for those in need.

Now that #GU25 is over, catch up on all the news from the meeting with #ASCODailyNews. All coverage of the Symposium's top research can be found here: https://lnkd.in/eCeCwbq3

That’s a wrap on #GU25! Thank you to everyone who made this year’s meeting a success. From groundbreaking science to insightful discussions, your contributions are driving progress in GU oncology. See you next year!

In our latest “Science in Seconds,” Dr. Bradley McGregor discusses two findings from the phase 3 TALAPRO-2 trial highlighting final overall survival with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment: one for unselected patients with metastatic castration-resistant prostate cancer (mCRPC) and one for patients with homologous recombination repair (HRR)-deficient #mCRPC. #GU25 https://lnkd.in/gRbjwKEy https://lnkd.in/gs2Cf4f3

Welcome to #GU25! Now that the Symposium has begun, stay up to date on the latest from San Francisco with #ASCODailyNews! Read in-depth coverage of newly presented prostate, kidney, and bladder cancer research here: https://lnkd.in/eCeCwbq3

Come together with us at the 2025 ASCO Annual Meeting. Embrace new opportunities and new connections with colleagues from around the world, immerse yourself in cutting-edge scientific research and discoveries, and add your voice to conversations that will transform tomorrow’s outcomes. Register today: https://brnw.ch/21wQEfp

Our new guideline on transoral robotic surgery for oropharyngeal squamous cell carcinoma (OPC) emphasizes multidisciplinary care. A key recommendation is a thorough history, physical exam, and fiberoptic laryngopharyngoscopy by a multidisciplinary team for all patients being evaluated for OPC. Read more: https://brnw.ch/21wQD6K